Australia is eagerly awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://miriamassf801218.eqnextwiki.com/6010935/novo_nordisk_s_retatrutide_australia_a_potential_breakthrough_for_losing_weight